CIK 0001737287
- Non-accelerated filer
- Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 823562771
- Phone
- +1 650-457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- 4 Derivatives Options or other derivatives
- 4 Grant or award Director acquired 16,498 shares (grant or award)
- 4 Grant or award Director acquired 16,498 shares (grant or award)
- 4 Exercise or conversion President and CEO acquired 27,410 shares (option exercise)
- 4 Exercise or conversion Chief Financial Officer acquired 14,897 shares (option exercise)
- 4 Exercise or conversion Director acquired 379,066 shares (option exercise)
- 4 Grant or award EVP of R&D and CMO acquired 200,534 shares (grant or award)
- 4 Open-market sale General Counsel sold 5,000 shares at $30.00 ($150,000)
- 4 Open-market sale General Counsel sold 5,000 shares at $28.30 ($141,476)
- 4 Open-market sale General Counsel sold 10,000 shares at an average $32.05 ($320,517)
- 4/A Gift President and CEO gave 411,556 shares (gift)
- 4 Grant or award Director acquired 53,635 shares (grant or award)
- 4 Grant or award President and CEO acquired 80,452 shares (grant or award)
- 4 Grant or award General Counsel acquired 22,202 shares (grant or award)
- 4 Grant or award Chief Technical Officer acquired 24,866 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 24,866 shares (grant or award)
- 4 Grant or award EVP of R&D and CMO acquired 24,866 shares (grant or award)
- 4 Open-market sale EVP of R&D and CMO sold 2,798 shares at $38.05 ($106,471)
- 4 Open-market sale President and CEO sold 20,513 shares at $38.57 ($791,271)
- 4 Open-market sale Chief Technical Officer sold 6,164 shares at $38.14 ($235,089)
Page 9 of 14 · 275 filings